The ASCO Genitourinary (GU) Cancers Symposium took place on the 17-19^th February 2022, in San Francisco, CA. Leading experts gave updates on trials in prostate cancer, urothelial carcinoma, renal cell carcinoma, and rare GU cancers, as well as discussing hot topics in the field.

In this podcast, we hear from several experts in the field of prostate cancer, as they update us on some of the biggest trials presented at ASCO GU 2022, including PROpel (NCT03732820), MAGNITUDE (NCT03748641), PRESIDE (NCT02288247), and ARASENS (NCT02799602). These four trials are investigating two ‘hot’ areas in prostate cancer research – PARP inhibitors and androgen receptor (AR) antagonists.